CD8A and neoplasm: Higher levels of tumor mutational burden, tumor PD‐L1, intratumoral CD8 positive T cells, interferon‐γ‐associated gene expression signature, and lower levels of peripheral serum C‐reactive protein were associated with improved RFS and OS with both nivolumab and ipilimumab, albeit with a limited clinically meaningful predictive value.